If Celgene is successful with this, then the BIO and PhRMA case for an IPR carve-out is surely destroyed. https://t.co/BRmUShU4L4
This will be interesting ... https://t.co/BRmUShU4L4
Interesting that the Bessen & Meurer $29bn claim dropped. But even this RPX amount largely made up of royalties. https://t.co/asQPp14HaT
The multi-year, worldwide and ongoing litigation battle between ZTE and non-practising entity (NPE) Vringo took an interesting twist last week when a series of internal ZTE documents were filed with a New York court. The documents, which largely consist of communications between ZTE staff, detail how the Chinese telecom company has set out to wage a “PR battle” against Vringo as...
Chinese investment firm GSR Capital yesterday announced the launch of a $5 billion M&A fund, which it said would be used for large-scale buyouts of western technology companies in sectors including life sciences, wireless communications and clean energy. Chairman Sonny Wu told Bloomberg that the firm will mainly target European businesses, in what could be another sign that the...
Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them
The pharmaceutical and biotechnology industries seem to be stepping up their attempts to secure a carve-out for biopharmaceutical patents from the IPR process. Last week, Jim Greenwood, the president and CEO of BIO and John Castellani, the president and CEO of PhRMA, put together an opinion piece for The Hill in which they claimed that: “Predatory hedge funds are short-selling the...
After several years of intensive growth in patent filings and grants, the Chinese government and businesses in the country are turning their attention to improving the strategic value of intellectual property. A group of industry insiders discuss the issues this raises
IAM Patent 1000
The definitive guide to leading patent lawyers, attorneys and firms in over 40 jurisdictions, with a special section on expert witnesses in the United States.Visit site